Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation
- 3 May 2021
- journal article
- letter
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (5), e69-e71
- https://doi.org/10.1016/j.jcf.2021.04.001
Abstract
No abstract availableKeywords
Funding Information
- NHLBI (R01 HL141286)
- National Institutes of Health (R01 HL141286)
This publication has 7 references indexed in Scilit:
- VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesThe New England Journal of Medicine, 2018
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesThe New England Journal of Medicine, 2018
- Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studiesJCI Insight, 2018
- Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical ImprovementAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young AdulthoodAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulatorsScientific Reports, 2017
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011